Oncology
🧪
Medicines not yet listed on the PBS or with limited TGA-registered availability through standard Australian oncology supply channels.
Oncology
🎯
EGFR, ALK, KRAS, BRAF and other precision oncology agents where PBS listing is pending or access through standard pathways presents challenges.
Oncology
🛡️
PD-1, PD-L1 and CTLA-4 checkpoint inhibitors — where PBS approval is pending, limited by indication, or access requires alternative pathways.
Oncology
🔬
Ultra-rare disease treatments and enzyme replacement therapies with no current TGA listing or limited authorised supply in Australia.
Oncology
💊
Medicines managing treatment side effects, maintaining patient function, and improving tolerability during active cancer treatment regimens.
Hematology
🩸
AML, CML, CLL and ALL medicines including BCR-ABL inhibitors, kinase inhibitors, and newer small molecule therapies with or without PBS listing.
Hematology
🔴
Treatments for Hodgkin's, non-Hodgkin's lymphoma, and multiple myeloma including proteasome inhibitors and monoclonal antibodies.
Hematology
🔢
Thrombopoietin receptor agonists and medicines managing immune thrombocytopenia (ITP) and related platelet disorder conditions.
Hematology
💉
Erythropoiesis-stimulating agents and immunosuppressive therapies for aplastic anaemia and blood production disorders.
Hematology
🧫
Factor replacement therapies and specialty medicines for haemophilia, clotting disorders, and anticoagulation management requiring prescription supply.
Women's Health
🌸
Treatments for endometriosis, PCOS, menopausal hormone therapy, and other hormone-dependent conditions where specialist access is required.
Women's Health
🎀
CDK4/6 inhibitors, aromatase inhibitors, PARP inhibitors, and HER2-targeted agents — including medicines pending PBS listing in Australia.
Women's Health
🩺
Medicines for ovarian, cervical, and uterine cancers including PARP inhibitors, ADC therapies, and targeted biologics not yet PBS-listed.
Women's Health
🤰
Fertility-related and reproductive support medicines where specialist prescription access or supply consistency presents challenges in Australia.
Men's Health
💙
Abiraterone acetate, enzalutamide, darolutamide, and androgen-pathway therapies for advanced prostate cancer, including newer agents.
Men's Health
🔷
Hormone replacement and androgen suppression therapies for male-specific endocrine conditions and hormone-related cancers requiring specialist prescription.
Men's Health
💪
Specialty medicines for testicular cancers, BPH, and male urological and genitourinary conditions supplied under valid prescription.
Men's Health
💊
Prescription erectile dysfunction medicines where supply continuity or specialist access may be a consideration for Australian patients.
HIV
🔵
First-, second-, and third-line ART including newer integrase strand transfer inhibitors and single-tablet combination regimens.
HIV
🧬
PrEP medicines for HIV prevention requiring valid prescription. All PrEP orders are handled with strict professional confidentiality and discreet packaging.
HIV
🩻
Medicines managing opportunistic infections, HIV-associated malignancies, and comorbid conditions in people living with HIV.
Hepatitis
🟡
Entecavir, tenofovir alafenamide (TAF), and other antiviral agents for chronic Hepatitis B management and liver protection.
Hepatitis
🟠
Pan-genotypic DAA regimens including sofosbuvir/velpatasvir combinations for Hepatitis C treatment in Australia.
Hepatitis
🫀
Supportive medicines for cirrhosis, liver fibrosis management, and hepatic complications arising from chronic viral hepatitis.